ORKA (STOCKS)
Oruka Therapeutics, Inc. Common Stock
$68.860000
-1.030000 (-1.47%)
Prev close: $69.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Lawrence O. Klein
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,158.52M
- Employees
- 28
- P/E (TTM)
- -28.80
- P/B (TTM)
- 7.25
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.48 | $-0.56 | +0.0802 | +14.32% |
|
Dec 2025 (Q4)
|
$-0.45 | $-0.64 | +0.1900 | +29.69% |
|
Sep 2025 (Q3)
|
$-0.55 | $-0.59 | +0.0431 | +7.27% |
|
Jun 2025 (Q2)
|
$-0.46 | $-0.50 | +0.0398 | +7.96% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $17.15M |
| Operating Expenses | $133.40M |
| Research and Development | $109.86M |
| Other Operating Expenses | $23.54M |
| Operating Income/Loss | -$133.40M |
| Income/Loss From Continuing Operations After Tax | -$116.25M |
| Income/Loss From Continuing Operations Before Tax | -$116.25M |
| Net Income/Loss | -$116.25M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$116.25M |
| Net Income/Loss Available To Common Stockholders, Basic | -$116.25M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $504.48M |
| Current Assets | $395.25M |
| Noncurrent Assets | $109.23M |
| Fixed Assets | $318.00K |
| Other Non-current Assets | $108.91M |
| Liabilities | $17.76M |
| Current Liabilities | $16.63M |
| Noncurrent Liabilities | $1.13M |
| Equity | $486.72M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $486.72M |
| Liabilities And Equity | $504.48M |
| Net Cash Flow From Operating Activities | -$90.92M |
| Net Cash Flow From Operating Activities, Continuing | -$90.92M |
| Net Cash Flow From Investing Activities | -$154.05M |
| Net Cash Flow From Investing Activities, Continuing | -$154.05M |
| Net Cash Flow From Financing Activities | $232.91M |
| Net Cash Flow From Financing Activities, Continuing | $232.91M |
| Net Cash Flow | -$12.06M |
| Net Cash Flow, Continuing | -$12.06M |
| Comprehensive Income/Loss | -$116.71M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$116.73M |
| Other Comprehensive Income/Loss | -$61.86M |